Avelumab (a PD-L1 inhibitor) and pemrolizumab (a PD-1 inhibitor) were approved by the Food and Drug Administration for the treatment of metastatic MCC in 2017 and 2019, respectively. This evidence concerns the gene CD274 and Merkel cell skin cancer.